Karyopharm Therapeutics (KPTI) PT Lowered to $43 at RBC Capital
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Price: $1.96 -2.97%
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 18 | New: 20
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 18 | New: 20
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $43.00 (from $45.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Aebi Schmidt Holding AG (AEBI) PT Raised to $17 at DA Davidson Following Q2 Results
- Johnson Rice Upgrades Magnolia Oil & Gas Corp. (MGY) to Accumulate
- MacroGenics (MGNX) PT Raised to $11 at B.Riley
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
